| Emily Hao-yun Liang, MD | |
|
4733 W Sunset Blvd, 3rd Floor, Los Angeles, CA 90027-6021 | |
| (323) 783-4516 | |
| Not Available |
| Full Name | Emily Hao-yun Liang |
|---|---|
| Gender | Female |
| Speciality | Allergy & Immunology |
| Location | 4733 W Sunset Blvd, Los Angeles, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164865358 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | A133700 (California) | Primary |
| Entity Name | South Bay Allergy & Asthma Assoc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528163334 PECOS PAC ID: 3173565694 Enrollment ID: O20050525000453 |
News Archive
Scientists at The Scripps Research Institute have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
Nearly one in five people suffers from the insidious and often devastating problem of chronic pain.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Retinoblastoma protein RB1, which is named after a form of pediatric tumor of the eye, is among the most common genetically regulated cellular proteins to malfunction in human cancer. RB1 was also the first tumor suppressor gene to be identified and its modes of inactivation in retinoblastoma tumors provided the basis for the ground-breaking two-hit hypothesis by the geneticist Alfred G. Knudson in the 70s, according to which cancer is due to the accumulation of multiple 'hits' or mutations in certain genes.
In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Hao-yun Liang, MD 4733 W Sunset Blvd, 3rd Floor, Los Angeles, CA 90027-6021 Ph: () - | Emily Hao-yun Liang, MD 4733 W Sunset Blvd, 3rd Floor, Los Angeles, CA 90027-6021 Ph: (323) 783-4516 |
News Archive
Scientists at The Scripps Research Institute have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
Nearly one in five people suffers from the insidious and often devastating problem of chronic pain.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Retinoblastoma protein RB1, which is named after a form of pediatric tumor of the eye, is among the most common genetically regulated cellular proteins to malfunction in human cancer. RB1 was also the first tumor suppressor gene to be identified and its modes of inactivation in retinoblastoma tumors provided the basis for the ground-breaking two-hit hypothesis by the geneticist Alfred G. Knudson in the 70s, according to which cancer is due to the accumulation of multiple 'hits' or mutations in certain genes.
In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.
› Verified 8 days ago
Dr. Robert W Eitches, Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 8631 W 3rd St, 925e, Los Angeles, CA 90048 Phone: 310-657-4600 Fax: 310-657-6020 | |
Renata G. Lubens, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-2000 | |
Dr. Barry Allen Kohn, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 7095 Hollywood Blvd, #635, Los Angeles, CA 90028 Phone: 323-436-0516 Fax: 323-436-0517 | |
Dr. Jean Marie Hanley, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 1801 E. Marengo St., L-902, Los Angeles County Usc Division Of Allergy, Los Angeles, CA 90033 Phone: 323-226-3823 Fax: 323-226-3732 | |
Richard M Harris, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1125 S Beverly Dr, Suite 740, Los Angeles, CA 90035 Phone: 310-275-0380 Fax: 310-275-1210 | |
Christina Hong Lee, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 11301 Wilshire Blvd, Bldg 500, 111r, Los Angeles, CA 90073 Phone: 310-478-3711 |